Agoniste Wnt II; SKL2001

Non disponible en dehors du Royaume-Uni et de l'Irlande

General description

A cell-permeable imidazolyl-isoxazolamide compound that upregulates β-catenin-regulated transcription (CRT; Effective conc. 10 - 40 µM) by blocking/disrupting β-catenin and Axin interaction, thereby preventing β-catenin phosphorylation (Ser³³/Ser³⁷/Thr⁴¹/Ser⁴⁵) and proteasomal degradation, without affecting the activities of GSK-3α/β or 18 other kinases (≤8.5% inhibition by 10 µM SKL2001). Wnt pathway activation by SKL2001 is shown to effectively promote osteoblastogenesis in both human and murine mesenchymal cultures (10 to 40 µM) as well as suppress MDI- (dexamethasone and insulin) stimulated adipogenesis of murine 3T3-L1 preadipocytes (5 to 30 µM).

A cell-permeable imidazolyl-isoxazolamide that upregulates β-catenin-regulated transcription (CRT; 10 - 40 µM) by disrupting β-catenin and Axin interaction, thereby preventing β-catenin phosphorylation (Ser³³/Ser³⁷/Thr⁴¹/Ser⁴⁵) and proteasomal degradation, without affecting the activities of GSK-3α/β or 18 other kinases (≤8.5% inhibition by 10 µM SKL2001). Shown to effectively promote osteoblastogenesis in both human and murine mesenchymal cultures (10 to 40 µM) as well as suppress MDI- (dexamethasone and insulin) stimulated adipogenesis of murine 3T3-L1 preadipocytes (5 to 30 µM).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Gwak, J., et al. 2012. Cell Res.22, 237.

Packaging

25 mg in Glass bottle

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)